|
Market Closed -
TEL AVIV STOCK EXCHANGE
23:24:49 26/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 2,407.00 ILa | +0.42% |
|
+1.78% | +6.50% |
| 10-06 | Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel | MT |
| 10-06 | Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Biopharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 445M | - | - | - | ||
| 1,135B | |||||
| 635B | |||||
| 505B | |||||
| 378B | |||||
| 358B |
- Stock Market
- Stocks
- KMDA Stock
- Charts Kamada Ltd.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
